Who Owns Phathom Pharmaceuticals Stock?
NASDAQ: PHATHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 92.31%
- Held by insiders
- 4.66%
- Institutional holders
- 226
- Institutions 92.3%
- Insiders 4.7%
- Public and other 3.0%
Who owns Phathom Pharmaceuticals stock?
Institutional investors own about 92.3% of Phathom Pharmaceuticals's shares, spread across 226 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.66% of PHAT.
The largest institutional holders are Frazier Life Sciences Management, L.P. (15.41%), Medicxi Ventures Management (Jersey) Ltd (9.23%) and Blackrock Inc. (5.59%). Together, the top 10 institutions control 54.5% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their PHAT positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of PHAT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12.47M | 15.41% | 0.0% |
| Medicxi Ventures Management (Jersey) Ltd | 7.46M | 9.23% | 0.0% |
| Blackrock Inc. | 4.53M | 5.59% | +11.4% |
| Invesco Ltd. | 4.03M | 4.98% | -6.8% |
| Carlyle Group Inc. | 3.50M | 4.32% | 0.0% |
| Millennium Management Llc | 3.38M | 4.17% | -16.1% |
| Vanguard Capital Management LLC | 2.66M | 3.28% | +2.8% |
| GW&K Investment Management, LLC | 2.17M | 2.68% | +52.5% |
| Franklin Resources, Inc. | 1.97M | 2.44% | +98.2% |
| NEA Management Company, LLC | 1.96M | 2.42% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of PHAT
| Fund | Shares | % Held |
|---|---|---|
| AIM Intl Mutual Fd.s -Invesco Global Fd. | 2.34M | 2.90% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.01M | 2.48% |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 1.36M | 1.68% |
| iShares Trust-iShares Russell 2000 ETF | 1.26M | 1.56% |
| IVY FUNDS-Nomura Small Cap Growth Fund | 988.51K | 1.22% |
| Franklin Strategic Series-FRANKLIN SMALL CAP GROWTH FUND | 827.07K | 1.02% |
| WASATCH FUNDS TRUST-Wasatch Micro Cap Fund | 806.56K | 1.00% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 586.63K | 0.73% |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 571.87K | 0.71% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 536.04K | 0.66% |
Frequently asked questions
Who is the largest shareholder of Phathom Pharmaceuticals?
Frazier Life Sciences Management, L.P. is the largest institutional shareholder of PHAT, owning 15.41% of shares outstanding (12.47M shares) as of its latest 13F filing.
What percentage of Phathom Pharmaceuticals is owned by institutions?
Institutions own about 92.3% of PHAT shares and 96.8% of the public float.
How much of Phathom Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 4.66% of PHAT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.